source
- Upcoming FDA decisions in Q3 2026 could signal agency flexibilityThe piece highlights five FDA actions slated for the third quarter of 2026 that industry participants are tracking. Observers say the outcomes may reveal how flexible the agency will be under its…
- Bristol Myers revises Phase 3 fibrosis trial after liver safety events, including a deathBristol Myers Squibb announced a change to its late-stage Phase 3 "Aloft" trial of the experimental pulmonary fibrosis drug admilparant. The amendment adds closer monitoring for liver-related adve…